ASYMCHEM

Asymchem Laboratories (Tianjin) Co., Ltd.
凱萊英醫藥集團(天津)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6821)

POSITIVE PROFIT ALERT

This announcement is made by Asymchem Laboratories (Tianjin) Co., Ltd. (凱萊英醫藥集團(天津)股份有限公司) (the "**Company**", collectively with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The following financial figures were prepared according to the China Accounting Standards for Business Enterprises.

I. ESTIMATED ANNUAL RESULTS OF 2021

1. Period for the estimated results: January 1, 2021 to December 31, 2021

2. Estimated results:

   The board of directors of the Company (the "**Board**") wishes to inform shareholders and potential investors of the Company that, based on preliminary estimation of the unaudited management accounts of the Group for the year ended December 31, 2021 by the finance department of the Company, and the information currently available to the Board:

   a. The revenue of the Company for the year of 2021 was estimated to be in a range between approximately RMB4,505 million and approximately RMB4,662 million, representing an increase by a range between approximately 43% and approximately 48% (approximately 52% and approximately 57% if exchange rate impacts excluded) as year-over-year increase, compared with RMB3,150 million for the year of 2020. Among which, the revenue of the Company for the fourth quarter of 2021 was estimated to be in a range between approximately RMB1,675 million and approximately RMB1,730 million, representing an increase by a range between approximately 57% and approximately 62% (approximately 62% and approximately 67% if exchange rate impacts excluded), compared with RMB1,067 million for the corresponding period in 2020.

   b. The net profit attributable to shareholders of the Company for the year of 2021 was estimated to be in a range between approximately RMB1,039.80 million and approximately RMB1,075.90 million, representing an increase by a range between approximately 44% and approximately 49% as year-over-year increase, compared with RMB722.09 million for the year of 2020.

c. The net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss for the year of 2021 was estimated to be in a range between approximately RMB908.00 million and approximately RMB940.20 million, representing an increase by a range between approximately 41% and approximately 46% as year-over-year increase, compared with RMB643.97 million for the year of 2020.

d. The basic earnings per share of the Company was estimated to be in a range between approximately RMB4.30 per share and approximately RMB4.60 per share, compared with RMB3.10 per share for the year of 2020.

3. The estimated results of this period are preliminary estimation by the finance department of the Company and have not been audited by the auditor of the Company. The Company has pre-communicated with the auditor of the Company on matters related to the estimated results, and there is no disagreement between the Company and the auditor of the Company on the estimated results.

II. MAIN REASONS FOR THE ESTIMATED CHANGE IN RESULTS FOR THE CURRENT PERIOD

1. Strong Growth in Small Molecule Business

In adherence to the business philosophy of "technology-driven, market-oriented and management-refined", the Company maintained the global leading position of small molecule CDMO solutions and has a strong growth in customer orders. The Company's revenue increased rapidly with new production capacity delivered in the second half of year in 2021. The Company's revenue generated from its small molecule business for the year of 2021 is expected to have a year-on-year increase of more than 45% (50% if exchange rate impacts excluded) as compared with the year of 2020. The Company's revenue generated from its small molecule business for the fourth quarter of 2021 is expected to have an increase of more than 65% (70% if exchange rate impacts excluded) as compared with the corresponding period in 2020.

2. Emerging Businesses Entering into Fast Track

In accordance with the "dual-wheel-drive" strategy, the Company has rapidly promoted the development of emerging business sectors such as chemical macromolecules, biological macromolecules CDMO, pharmaceutical preparations, clinical CRO, etc. The Company's revenue generated from the emerging business sectors for the year of 2021 is expected to have a year-on-year increase of more than 65% (70% if exchange rate impacts excluded) as compared with the year of 2020.

III. OTHER RELEVANT INFORMATION

The estimated results disclosed in this announcement is only a preliminary estimate made by the finance department of the Company and has not been audited by the auditor of the Company. Please refer to the announcement of the audited 2021 annual results of the Company to be published subsequently for the finalized financial information. The Company is still in the process of finalizing the annual results for the year ended December 31, 2021. Financial information and other information of the Company for the year ended December 31, 2021 will be disclosed in the annual results announcement for the year ended December 31, 2021 in accordance with the requirements of the Listing Rules which is expected to be published on or before March 31, 2022. Investors are advised to pay attention to any associated investment risks.

The shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Asymchem Laboratories (Tianjin) Co., Ltd.
Dr. Hao Hong
Chairman of the Board, Executive Director and Chief Executive Officer

Tianjin, January 25, 2022

As of the date of this announcement, the Board of Directors of the Company comprises Dr. Hao Hong as the Chairman of the Board of Directors and executive Director, Ms. Yang Rui, Mr. Zhang Da and Mr. Hong Liang as executive Directors, Dr. Ye Song and Ms. Zhang Ting as non-executive Directors, and Ms. Zhang Kun, Mr. Wang Qingsong and Mr. Lee, Kar Chung Felix as independent non-executive Directors.